When was Juno Therapeutics founded?

Juno Therapeutics was founded in 2013 and raised its 1st funding round within a year of its incorporation.

Where is Juno Therapeutics located?

Juno Therapeutics is headquartered in Seattle, United States.

How many employees does Juno Therapeutics have?

As of May 31, 2026, the latest employee count at Juno Therapeutics is 93.

Is Juno Therapeutics a funded company?

Juno Therapeutics is a funded company, having raised a total of $317M across 5 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Dec 26, 2013.

How much is Juno Therapeutics worth?

The last known valuation of Juno Therapeutics was $***** as of Jan 01, 2014.

When was the latest funding round of Juno Therapeutics?

Juno Therapeutics' latest funding was a $***** Post IPO round on Oct 05, 2017, with participation from 0 investor.

What is the annual revenue of Juno Therapeutics?

Annual revenue of Juno Therapeutics is between $100M and $500M as on Dec 31, 2017

Where does Juno Therapeutics rank among its competitors?

Juno Therapeutics ranks 19th amongst 1849 active competitors, of which 96 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was AstraZeneca, which secured $6.05M in Jul, 2025.

Who are the top competitors of Juno Therapeutics?

Juno Therapeutics' top competitors include AbbVie, Gilead and Amgen. Among them, AstraZeneca secured the most recent funding round in July, 2025.

Juno Therapeutics - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Global biopharmaceutical company discovering, developing, and delivering innovative medicines. Focused on cutting-edge science and research, the company develops a multitude of treatment modalities. It offers resources for patients, caregivers, and healthcare providers, including medical information, clinical trials, and patient support programs. The company is committed to global inclusion and diversity, making a positive impact on communities worldwide. It fosters partnerships and collaborations to accelerate the development of new medicines. The company focuses on areas such as immunology, oncology, and other serious diseases. It is dedicated to improving patient outcomes and transforming lives through science. The company also provides resources for investors and media, including financial reporting, press releases, and corporate information.

Website: junotherapeutics.com
Social

Key Metrics

Founded Year

2013

Location

Seattle, United States

Stage

Acquired

Total Funding

$317M in 5 rounds

Latest Funding Round

Post IPO, Oct 05, 2017, $*****

Last Known Valuation

$***** as on Jan 01, 2014

Investors

Venrock & 15 more

Ranked

19^th among 1849 active competitors

Annual Revenue

$100M - $500M as on Dec 31, 2017

Employee Count

93 as on May 31, 2026

Investment & Acquisitions

JW Therapeutics & 5 more

Similar Companies

AbbVie & 1877 more

Exit Details

Acquired by TQ Therapeutics (May 28, 2025)

View Juno Therapeutics' full profile

Juno Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Juno Therapeutics, Inc. CIN: 1594864 , United States, Active	Aug 04, 2013	$100M - $500M (As on Dec 31, 2017)	730 (As on Dec 31, 2022)	-

Juno Therapeutics got acquired by TQ Therapeutics on May 28, 2025.

Click here to take a look at Juno Therapeutics's acquisition in detail

Juno Therapeutics has raised a total funding of $317M over 5 rounds. Its first funding round was on Dec 26, 2013. Juno Therapeutics has 16 institutional investors.

Here is the list of recent funding rounds of Juno Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 05, 2017	5028213	Post IPO	4255234	2544947	5208012	4999058
Jun 29, 2017	1221574	Post IPO	9903785	7439621	7683204	3886458
Aug 14, 2014	9578319	Series B	4733434	7232706	5053614	4455429

Access funding benchmarks and valuations. Sign up today!

View details of Juno Therapeutics's funding rounds and investors

Juno Therapeutics' employee count trend

Juno Therapeutics has 93 employees as of May 26. Here is Juno Therapeutics's employee count trend over the years:

Employee count trend for Juno Therapeutics

Uncover Juno Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Juno Therapeutics include AbbVie, Gilead and Amgen. Here is the list of Top 10 competitors of Juno Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	AbbVie 2012, Chicago (United States), Public	Research-based biopharmaceutical company	$14.7B	Berkshire Hathaway, Alcor Fund & 9 others	83/100
2nd	Gilead 1987, Foster City (United States), Acquired	Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others	-	BB Biotech, Jindal ventures & 17 others	81/100
3rd	Amgen 1980, Thousand Oaks (United States), Public	Developer of pharmaceutical products for treating multiple diseases	-	Digital Pharma Lab, Amgen Business Development ... & 11 others	79/100
4th	AstraZeneca 1999, Cambridge (United Kingdom), Public	Developer of pharmaceutical medicines for oncology and various chronic diseases	-	Digital Pharma Lab, Columbia Capital & 13 others	76/100
5th	Lilly 1876, Indianapolis (United States), Public	Developer of traditional pharmaceutical medicines	-	Alcor Fund, Digital Pharma Lab & 11 others	75/100
6th	Johnson & Johnson 1886, New Brunswick (United States), Public	Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products	-	Western Technology Investment, Alcor Fund ... & 16 others	74/100
7th	Roivant Sciences 2014, New York City (United States), Public	Developer of therapeutics to treat neurology, oncology, rare, and endocrinology based diseases	$1.3B	SoftBank Vision Fund, NovaQuest Capital Management ... & 8 others	72/100
8th	Novartis 1996, Basel (Switzerland), Acquired	R&D focused on manufacturing of drugs for multiple therapeutic areas	-	Digital Pharma Lab, Atlas Venture & 9 others	71/100
9th	Roche 1896, Basel (Switzerland), Public	Developer of pharmaceuticals and diagnostics kits	-	Gilde Healthcare, SoftBank Group & 11 others	70/100
10th	Genentech 1976, San Francisco (United States), Acquired	R&D company focused on manufacturing drugs for multiple therapeutic areas	$72.5M	Ignite 500, The Column Group & 4 others	68/100
19th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	Venrock, Foresite Capital & 14 others	65/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Juno Therapeutics's competitors? Click here to see the top ones

Juno Therapeutics has made 2 investments in companies including JW Therapeutics and Editas Medicine. Juno Therapeutics has also acquired 4 companies including AbVitro and XBody.

Here is the list of investments & acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Mar 07, 2018	Investments	JW Therapeutics	2016	Shanghai (China)
Jan 11, 2016	Acquisition	AbVitro	2012	Boston (United States)
Jun 02, 2015	Acquisition	XBody	2010	Gyor (Hungary)